JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

CareDx Inc

Geschlossen

BrancheGesundheitswesen

19.35 6.09

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.16

Max

19.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

10M

1.7M

Verkäufe

13M

100M

KGV

Branchendurchschnitt

15.953

84.243

Gewinnspanne

1.674

Angestellte

644

EBITDA

11M

6.8M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-7.55% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

25. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

301M

1.1B

Vorheriger Eröffnungskurs

13.26

Vorheriger Schlusskurs

19.35

Nachrichtenstimmung

By Acuity

80%

20%

328 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

CareDx Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Feb. 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8. Feb. 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8. Feb. 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8. Feb. 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Feb. 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8. Feb. 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8. Feb. 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8. Feb. 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8. Feb. 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7. Feb. 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. Feb. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Feb. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Feb. 2026, 02:46 UTC

Akquisitionen, Fusionen, Übernahmen

Big Money, High Anxiety -- Barrons.com

6. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 21:40 UTC

Akquisitionen, Fusionen, Übernahmen

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. Feb. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. Feb. 2026, 21:17 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Feb. 2026, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. Feb. 2026, 21:13 UTC

Ergebnisse

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. Feb. 2026, 21:13 UTC

Ergebnisse

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. Feb. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. Feb. 2026, 20:34 UTC

Ergebnisse

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Peer-Vergleich

Kursveränderung

CareDx Inc Prognose

Kursziel

By TipRanks

-7.55% Nachteil

12-Monats-Prognose

Durchschnitt 18 USD  -7.55%

Hoch 18 USD

Tief 18 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CareDx Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

0

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

14.77 / 18.49Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

328 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat